Skip to main content
. 2025 Feb 26;17(3):306. doi: 10.3390/pharmaceutics17030306
AIE aggregation induced emission
AP3 ansamitocin P3
ATP adenosine triphosphate
BP black phosphorus
BSA bovine serum albumin
CDT chemodynamic therapy
Ce6 chlorin e6
CeO2 cerium dioxide
CuO copper oxide
Cur curcumin
DAMPs damage-associated molecular patterns
DOX doxorubicin
Er erlotinib
FA folic acid
GAL galactose
GBP glycopican 3 binding peptide
gel incorporating hydrogel
GO graphene oxide
GOx glucose oxidase
GSH glutathione
HA hyaluronic acid
Hb hemoglobin
HMSNs hollow mesoporous silica nanoparticles
ICG indocyanine green
ICPs infinite coordination polymer
LM liquid metal
MGO modified graphene oxide
MN metronidazole
mPDA mesoporous polydopamine
MPE maximum permissible exposure
MSNs mesoporous silica nanoparticles
NIR near-infrared
NPs nanoparticles
PA pheophorbide A
PAA polyacrylic acid
PBA phenylboronic acid
PBNPs prussian blue nanoparticles
PDT photodynamic therapy
PEG polyethylene glycol
PEI polyethylenimine
PHC porphyrin-derivative hybrid complex
PPIX protoporphyrin IX
PTAs photothermal agents
PTT photothermal therapy
RBL1/p107 retinoblastoma-like protein 1
RGD aspartic acid
ROS reactive oxygen species
RT radiotherapy
SA sodium alginate
SDT sonodynamic therapy
SFB sorafenib
SOD superoxide dismutase
TCA thyrocalcitonin
TF transferrin
TME tumor microenvironment
TPZ tirapazamine
V vanadium
VIO nanoparticles
ZnPc zinc phthalocyanine